Proactive Investors - Run By Investors For Investors

Redx Pharma secures short-term funding; assessing longer-term solutions

A loan of up to £2.5mln is being provided by 18.6% shareholder Moulton Goodies
scientist filling sample tray
In the meantime work continues: Initial results from a phase I study of its lead drug, RXC004, a porcupine inhibitor aimed at treating cancer driven by the Wnt pathway, are expected in the second half of the year

Redx Pharma (LON:REDX) has secured short-term funding with a loan of up to £2.5mln and is in talks to find a longer-term financing solution.

Shareholder Moulton Goodies Ltd has agreed to provide the secured loan note facility, with £1mln being drawn down immediately. The coupon is 10% a year and there is an option to turn the debt into equity in certain circumstances.

At the same time boss Lisa Anson and her executive team remain in “active discussions” with shareholders and “third-party healthcare specialist investors” to find a more sustainable and efficient method of bankrolling the group.

Value realisation 

Investors were told Redx is also looking to “pursue potential value realisation opportunities” for its pan-RAF cancer research programme. 

“The company will provide further updates in due course,” the firm added.

The loan runs until the end of the year and can be capitalised in the event of an equity fundraiser of at least £10mln (though there are provisions to turn the debt into shares at a lesser amount). Moulton, which owns 18.6% of Redx, would receive new shares at a discount to the price they are offered.

As the lender owns such a large chunk of the business it is being treated as what’s called a related-party transaction under AIM’s rules. Therefore, Redx took advice before agreeing the financing deal.

“The board consider that the terms of the loan are fair and reasonable insofar as the company's shareholders are concerned, having consulted with Cantor Fitzgerald Europe, the company's nominated adviser,” shareholders were told.

Results update

In a separate update, Redx published financial results for the six months to the end of March, which showed the company had £3.3mln in the bank at that point, although operating expenses for the period were £5mln.

Initial results from a phase I study of its lead drug, RXC004, a porcupine inhibitor aimed at treating cancer driven by the Wnt pathway, are expected in the second half of the year, with the full read-out expected in early 2020.

Currently one patient has received a first cycle of treatment with two joining the first group soon. Redx believes the “required exposures” to the drug will be in the 0.5-3mg range.

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies
man with erectile dysfunction
June 17 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use